AbbVie (ABBV) lowers 2025 adj. EPS guidance to USD 9.90-9.94 including milestones expense; Q4 25 view adj. EPS 2.61-2.65

AbbVie's revision of its 2025 adjusted EPS guidance down to USD 9.90-9.94 reflects increased milestone expenses, which could signal underlying pressures on profitability.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Jefferies (JEF) Q4 2025 (USD): Adj. EPS 0.94 (exp. 0.94), Revenue 2.069bln (exp. 2.0bln)

Mobileye (MBLY) clarifies CES guidance of FY25 revenue just short of USD 2bln (exp. 1.88bln) as a way to describe size of business at the moment, not precise indication of actual revenue

AbbVie (ABBV) lowers 2025 adj. EPS guidance to USD 9.90-9.94 including milestones expense; Q4 25 view adj. EPS 2.61-2.65

Exxon Mobil (XOM) says change in industry margins to impact Q4 energy products earnings by USD 0.3-0.7bln vs Q3; change in gas prices to impact Q4 upstream earnings by USD -0.3-0.1bln

Constellation Brands Inc (STZ) Q3 2026 (USD) Adj. EPS 3.06 (exp. 2.64), Revenue 2.22bln (exp. 2.16bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This may also influence investor sentiment, as adjusted EPS for Q4 2025 is projected between 2.61-2.65, suggesting cautious outlook for growth amidst ongoing financial adjustments. Watch for potential sector implications, particularly in biotechnology, and how this shapes investor expectations in upcoming sessions.

Related headlines

The whole workspace, free to try.

Try it free